Growing Uptake in Cancer Diagnostics and Therapeutics Open New Frontiers in Radiopharmaceutical Market, Valuation Predicted to Touch ~US$ 5.4 Bn by 2027, TMR
Increasing deployment of
99m Tc Isotope in disease diagnostic and other emerging applications of nuclear medicine to thrive on multi-disciplinary research
-
Players aim at complying with stringent regulatory guidelines to develop new radiopharmaceuticals
ALBANY, N.Y., April 14, 2021 /PRNewswire/ -- The use of radiopharmaceuticals as a therapeutic modality is gaining traction in neurology, oncology, and cardiology. The expanding array of radiopharmaceutical agents is enriching the arena of radiopharmaceutical therapy and advancing its use in metastatic cancer. The growing number of radiopharmaceuticals approved for therapy by the FDA is a key trend expanding the frontiers in radiopharmaceuticals market. The therapies show the combined efficacy of chemotherapy and targeted biologic therapy. The expanding avenue of nuclear medicine imaging for diagnosing, staging, and treating diseases is shaping the evolution of the radiopharmaceuticals market. Technetium - 99 is one of the prominent radiopharmaceuticals that have been adopted for panoply of diagnostic procedures, on the back of the availability of short-lived